{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:34:14Z","timestamp":1794270854536,"version":"4.9.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We have previously recognized the genotypic and prognostic heterogeneity of\n                    <jats:italic>U2AF1<\/jats:italic>\n                    mutations (MT) in myelofibrosis (MF) and myelodysplastic syndromes (MDS). In the current study, we considered 179\n                    <jats:italic>U2AF1<\/jats:italic>\n                    -mutated patients with clonal cytopenia of undetermined significance (CCUS;\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200922), MDS (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009108), MDS\/acute myeloid leukemia (AML;\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200918) and AML (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200931).\n                    <jats:italic>U2AF1<\/jats:italic>\n                    variants included S34 (60%), Q157 (35%), and others (5%): corresponding mutational frequencies were 45%, 55%, and 0% in CCUS; 57%, 39%, and 4% in MDS; 61%, 33%, and 6% in MDS\/AML; and 55%, 35% and 10% in AML (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.17, 0.36 and 0.09), respectively. Concurrent mutations included\n                    <jats:italic>ASXL1<\/jats:italic>\n                    (37%),\n                    <jats:italic>BCOR<\/jats:italic>\n                    (19%),\n                    <jats:italic>RUNX1<\/jats:italic>\n                    (14%),\n                    <jats:italic>TET2<\/jats:italic>\n                    (15%),\n                    <jats:italic>DNMT3A<\/jats:italic>\n                    (10%),\n                    <jats:italic>NRAS<\/jats:italic>\n                    \/\n                    <jats:italic>KRAS<\/jats:italic>\n                    (8%),\n                    <jats:italic>TP53<\/jats:italic>\n                    (8%),\n                    <jats:italic>JAK2<\/jats:italic>\n                    (5.5%) and\n                    <jats:italic>SETBP1<\/jats:italic>\n                    (5%). The two most frequent\n                    <jats:italic>U2AF1<\/jats:italic>\n                    MT were S34F (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200997) and Q157P (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200946); concurrent MT were more likely to be seen with the latter (91% vs 74%;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.01) and abnormal karyotype with the former (70% vs 62%;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.05).\n                    <jats:italic>U2AF1<\/jats:italic>\n                    S34F MT clustered with\n                    <jats:italic>BCOR<\/jats:italic>\n                    (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.04) and Q157P MT with\n                    <jats:italic>ASXL1<\/jats:italic>\n                    (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.01) and\n                    <jats:italic>TP53<\/jats:italic>\n                    (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.03). The median overall survival (OS) in months was significantly worse in AML (14.2) vs MDS\/AML (27.3) vs MDS (33.7;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.001); the latter had similar OS with CCUS (30.0). In morphologically high-risk disease (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200949), defined by \u226510% blood or bone marrow blasts (i.e., AML or MDS\/AML), median OS was 14.2 with Q157P vs 37.1 months in the presence of S34F (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.008); transplant-adjusted multivariable analysis confirmed the detrimental impact of Q157P (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.01) on survival and also identified\n                    <jats:italic>JAK2<\/jats:italic>\n                    MT as an additional risk factor (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.02). OS was favorably affected by allogeneic hematopoietic stem cell transplantation (HR: 0.16, 95% CI; 0.04-0.61,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.007). The current study defines the prevalence and co-mutational profiles of\n                    <jats:italic>U2AF1<\/jats:italic>\n                    pathogenic variants in AML, MDS\/AML, MDS, and CCUS, and suggests prognostic heterogeneity in patients with \u226510% blasts.\n                  <\/jats:p>","DOI":"10.1038\/s41408-023-00922-7","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T10:03:07Z","timestamp":1695290587000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1548-918X","authenticated-orcid":false,"given":"Talha","family":"Badar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yenny A. Moreno","family":"Vanegas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5247-5065","authenticated-orcid":false,"given":"Ahmad","family":"Nanaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1673-1708","authenticated-orcid":false,"given":"James M.","family":"Foran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0824-3715","authenticated-orcid":false,"given":"Aref","family":"Al-Kali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2458-9887","authenticated-orcid":false,"given":"Abhishek","family":"Mangaonkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemant","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan B.","family":"Alkhateeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Viswanatha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6116-8163","authenticated-orcid":false,"given":"Rong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5359-336X","authenticated-orcid":false,"given":"Mithun","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia Arana","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9816-6302","authenticated-orcid":false,"given":"Mark R.","family":"Litzow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-6172","authenticated-orcid":false,"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4605-3821","authenticated-orcid":false,"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6998-662X","authenticated-orcid":false,"given":"Mrinal M.","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,21]]},"reference":[{"key":"922_CR1","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1080\/10428194.2020.1719089","volume":"61","author":"T Badar","year":"2020","unstructured":"Badar T, Szabo A, Sallman D, Komrojki R, Lancet J, Padron E, et al. Interrogation of molecular profiles can help in differentiating between MDS and AML with MDS-related changes. Leuk Lymphoma. 2020;61:1418\u201327.","journal-title":"Leuk Lymphoma"},{"key":"922_CR2","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","volume":"125","author":"RC Lindsley","year":"2015","unstructured":"Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125:1367\u201376.","journal-title":"Blood."},{"key":"922_CR3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/ajcp\/aqw016","volume":"145","author":"E Reinig","year":"2016","unstructured":"Reinig E, Yang F, Traer E, Arora R, Brown S, Rattray R, et al. Targeted next-generation sequencing in myelodysplastic syndrome and chronic myelomonocytic leukemia aids diagnosis in challenging cases and identifies frequent spliceosome mutations in transformed acute myeloid leukemia. Am J Clin Pathol. 2016;145:497\u2013506.","journal-title":"Am J Clin Pathol"},{"key":"922_CR4","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1182\/blood-2011-12-399337","volume":"119","author":"F Thol","year":"2012","unstructured":"Thol F, Kade S, Schlarmann C, L\u00f6ffeld P, Morgan M, Krauter J, et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood. 2012;119:3578\u201384.","journal-title":"Blood."},{"key":"922_CR5","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nature10496","volume":"478","author":"K Yoshida","year":"2011","unstructured":"Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478:64\u20139.","journal-title":"Nature."},{"key":"922_CR6","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1182\/bloodadvances.2020004173","volume":"5","author":"CA Lachowiez","year":"2021","unstructured":"Lachowiez CA, Loghavi S, Furudate K, Montalban-Bravo G, Maiti A, Kadia T, et al. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Adv. 2021;5:2173\u201383.","journal-title":"Blood Adv"},{"key":"922_CR7","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood."},{"key":"922_CR8","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1182\/blood-2018-04-843771","volume":"132","author":"A Pellagatti","year":"2018","unstructured":"Pellagatti A, Armstrong RN, Steeples V, Sharma E, Repapi E, Singh S, et al. Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes\/pathways and clinical associations. Blood. 2018;132:1225\u201340.","journal-title":"Blood."},{"key":"922_CR9","doi-asserted-by":"crossref","unstructured":"Zhao Y, Cai W, Hua Y, Yang X, Zhou J. The biological and clinical consequences of RNA splicing factor U2AF1 mutation in myeloid malignancies. Cancers. 2022;14:4406.","DOI":"10.3390\/cancers14184406"},{"key":"922_CR10","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1038\/s41375-018-0078-0","volume":"32","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Finke CM, Lasho TL, Hanson CA, Ketterling RP, Gangat N, et al. U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions. Leukemia. 2018;32:2274\u20138.","journal-title":"Leukemia."},{"key":"922_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.22","volume":"6","author":"D Barraco","year":"2016","unstructured":"Barraco D, Elala YC, Lasho TL, Begna KH, Gangat N, Finke C, et al. Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations. Blood Cancer J. 2016;6:e415.","journal-title":"Blood Cancer J"},{"key":"922_CR12","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41586-018-0317-6","volume":"559","author":"S Abelson","year":"2018","unstructured":"Abelson S, Collord G, Ng SWK, Weissbrod O, Mendelson Cohen N, Niemeyer E, et al. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature. 2018;559:400\u20134.","journal-title":"Nature."},{"key":"922_CR13","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/s41591-022-01883-3","volume":"28","author":"NA Robertson","year":"2022","unstructured":"Robertson NA, Latorre-Crespo E, Terradas-Terradas M, Lemos-Portela J, Purcell AC, Livesey BJ, et al. Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects. Nat Med. 2022;28:1439\u201346.","journal-title":"Nat Med"},{"key":"922_CR14","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1182\/blood-2017-01-763425","volume":"129","author":"L Malcovati","year":"2017","unstructured":"Malcovati L, Galli A, Travaglino E, Ambaglio I, Rizzo E, Molteni E, et al. Clinical significance of somatic mutation in unexplained blood cytopenia. Blood. 2017;129:3371\u20138.","journal-title":"Blood."},{"key":"922_CR15","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1182\/blood.V128.22.3155.3155","volume":"128","author":"V Adema","year":"2016","unstructured":"Adema V, Hirsch CM, Przychodzen BP, Nazha A, Kuzmanovic T, Negoro E. et al. U2AF1 mutations in S34 and Q157 create distinct molecular and clinical contexts. Blood.2016;128:3155","journal-title":"Blood."},{"key":"922_CR16","doi-asserted-by":"publisher","first-page":"107007","DOI":"10.1016\/j.leukres.2022.107007","volume":"125","author":"SL Pritzl","year":"2023","unstructured":"Pritzl SL, Gurney M, Badar T, Ferrer A, Lasho T, Finke C, et al. Clinical and molecular spectrum and prognostic outcomes of U2AF1 mutant clonal hematopoiesis\u2014a prospective Mayo Clinic cohort study. Leuk Res. 2023;125:107007.","journal-title":"Leuk Res"},{"key":"922_CR17","doi-asserted-by":"publisher","first-page":"E146","DOI":"10.1002\/ajh.25084","volume":"93","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Mudireddy M, Finke CM, Nicolosi M, Lasho TL, Hanson CA, et al. U2AF1 mutation variants in myelodysplastic syndromes and their clinical correlates. Am J Hematol. 2018;93:E146\u2013E8.","journal-title":"Am J Hematol"},{"key":"922_CR18","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka H-M, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood."},{"key":"922_CR19","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia."},{"key":"922_CR20","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347.","journal-title":"Blood."},{"key":"922_CR21","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419\u201325.","journal-title":"Blood."},{"key":"922_CR22","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sol\u00e9 F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454\u201365.","journal-title":"Blood."},{"key":"922_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/ng.1031","volume":"44","author":"TA Graubert","year":"2012","unstructured":"Graubert TA, Shen D, Ding L, Okeyo-Owuor T, Lunn CL, Shao J, et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet. 2012;44:53\u20137.","journal-title":"Nat Genet"},{"key":"922_CR24","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/gcc.22510","volume":"57","author":"B Li","year":"2018","unstructured":"Li B, Liu J, Jia Y, Wang J, Xu Z, Qin T, et al. Clinical features and biological implications of different U2AF1 mutation types in myelodysplastic syndromes. Genes Chromosomes Cancer. 2018;57:80\u20138.","journal-title":"Genes Chromosomes Cancer"},{"key":"922_CR25","doi-asserted-by":"publisher","first-page":"E277","DOI":"10.1002\/ajh.23541","volume":"88","author":"S-J Wu","year":"2013","unstructured":"Wu S-J, Tang J-L, Lin C-T, Kuo Y-Y, Li L-Y, Tseng M-H, et al. Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression. Am J Hematol. 2013;88:E277\u201382.","journal-title":"Am J Hematol"},{"key":"922_CR26","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1038\/s41375-020-0839-4","volume":"34","author":"SA Bamopoulos","year":"2020","unstructured":"Bamopoulos SA, Batcha AMN, Jurinovic V, Rothenberg-Thurley M, Janke H, Ksienzyk B, et al. Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia. Leukemia. 2020;34:2621\u201334.","journal-title":"Leukemia"},{"key":"922_CR27","doi-asserted-by":"publisher","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","volume":"1","author":"E Bernard","year":"2022","unstructured":"Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Ossa JEA, Nannya Y, et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evidence. 2022;1:EVIDoa2200008.","journal-title":"NEJM Evidence"},{"key":"922_CR28","doi-asserted-by":"publisher","first-page":"55264","DOI":"10.18632\/oncotarget.10526","volume":"7","author":"SH Jung","year":"2016","unstructured":"Jung SH, Kim YJ, Yim SH, Kim HJ, Kwon YR, Hur EH, et al. Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome. Oncotarget. 2016;7:55264\u201375.","journal-title":"Oncotarget."},{"key":"922_CR29","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1038\/s41409-022-01817-0","volume":"57","author":"G-Y Song","year":"2022","unstructured":"Song G-Y, Kim T, Ahn S-Y, Jung S-H, Kim M, Yang D-H, et al. Allogeneic hematopoietic cell transplantation can overcome the adverse prognosis indicated by secondary-type mutations in de novo acute myeloid leukemia. Bone Marrow Transplant. 2022;57:1810\u20139.","journal-title":"Bone Marrow Transplant"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00922-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00922-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00922-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T20:06:55Z","timestamp":1700338015000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00922-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,21]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["922"],"URL":"https:\/\/doi.org\/10.1038\/s41408-023-00922-7","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,21]]},"assertion":[{"value":"29 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"149"}}